0630 (0630) Fair Value & Analysis

Healthcare · Market cap HK$209M

0 0630 0630 · HK

PriceHK$0.2160

Fair ValueHK$0.1200

Upside-44.4%

Quality54/100

Evidence: High Range HK$0.0800 – HK$0.1500

Fair value as of: Jul 2, 2026

From 21 valuation models · updated today

Share price −22.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1000 – HK$0.4250 · fair‑value band HK$0.0800 – HK$0.1500 · the HK$0.2160 price screens above the HK$0.1200 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0630 (0630) currently trades at HK$0.2160, while our model-based Fair Value estimate is HK$0.1200 — implying the stock looks roughly 44.4% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 0630 generated revenue of HK$68.4M at a net margin of 86.5%. Revenue grew 161.1% year over year. It earns a return on equity of 65.9%. Net debt stands at HK$17.7M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$68.4M

Revenue growth (YoY) +161%

Net margin 86.5%

Return on equity 65.9%

Free cash flow HK$8.1M FY2025

P/E ratio 3.6

More key figures

Operating margin 32.0%

EPS growth (YoY) +140%

Net debt HK$17.7M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0630 reported revenue of HK$68.4M in FY2025 versus HK$71.9M in FY2021, a compound −1.3%/yr. Reported net income was HK$59.1M in FY2025.

Revenue −1.3%/yr

FY21 HK$71.9M

FY22 HK$66.5M

FY23 HK$34.3M

FY24 HK$37.8M

FY25 HK$68.4M

Net income

FY21 −HK$18.1M

FY22 −HK$104M

FY23 −HK$2.8M

FY24 −HK$1.2M

FY25 HK$59.1M

Is 0630 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$412.02	$165.35	-60%
EssilorLuxottica Société anonyme ESLOF	$192.00	$126.51	-34%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$34.71	$30.15	-13%
Becton, Dickinson and Company BDX	$140.71	$104.17	-26%
Alcon Inc ALC	$66.58	$36.99	-44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0630 (0630) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.1200 versus a price of HK$0.2160 — about −44% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0630?

Our model-based fair value for 0630 is HK$0.1200 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2160.

What is the quality score of 0630?

0630 has a Quality Score of 54/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0630 (0630)?

0630 reported trailing-twelve-month revenue of about HK$68.4M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0630?

The net profit margin of 0630 is about 86.5%, meaning it keeps roughly 86.5% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.